spacer
spacer

PDBsum entry 2aew

Go to PDB code: 
protein Protein-protein interface(s) links
Hormone/growth factor PDB id
2aew

 

 

 

 

Loading ...

 
JSmol PyMol  
Contents
Protein chains
189 a.a. *
188 a.a. *
Waters ×37
* Residue conservation analysis
PDB id:
2aew
Name: Hormone/growth factor
Title: A model for growth hormone receptor activation based on subunit rotation within a receptor dimer
Structure: Growth hormone receptor. Chain: a, b. Fragment: residues 29-233. Engineered: yes
Source: Homo sapiens. Human. Organism_taxid: 9606. Expressed in: escherichia coli. Expression_system_taxid: 562
Resolution:
2.70Å     R-factor:   0.257     R-free:   0.302
Authors: J.J.Adams,W.J.Mckinstry,M.W.Parker,M.J.Waters
Key ref:
R.J.Brown et al. (2005). Model for growth hormone receptor activation based on subunit rotation within a receptor dimer. Nat Struct Mol Biol, 12, 814-821. PubMed id: 16116438 DOI: 10.1038/nsmb977
Date:
24-Jul-05     Release date:   01-Nov-05    
PROCHECK
Go to PROCHECK summary
 Headers
 References

Protein chain
Pfam   ArchSchema ?
P10912  (GHR_HUMAN) -  Growth hormone receptor from Homo sapiens
Seq:
Struc:
 
Seq:
Struc:
638 a.a.
189 a.a.
Protein chain
Pfam   ArchSchema ?
P10912  (GHR_HUMAN) -  Growth hormone receptor from Homo sapiens
Seq:
Struc:
 
Seq:
Struc:
638 a.a.
188 a.a.
Key:    PfamA domain  Secondary structure  CATH domain

 

 
DOI no: 10.1038/nsmb977 Nat Struct Mol Biol 12:814-821 (2005)
PubMed id: 16116438  
 
 
Model for growth hormone receptor activation based on subunit rotation within a receptor dimer.
R.J.Brown, J.J.Adams, R.A.Pelekanos, Y.Wan, W.J.McKinstry, K.Palethorpe, R.M.Seeber, T.A.Monks, K.A.Eidne, M.W.Parker, M.J.Waters.
 
  ABSTRACT  
 
Growth hormone is believed to activate the growth hormone receptor (GHR) by dimerizing two identical receptor subunits, leading to activation of JAK2 kinase associated with the cytoplasmic domain. However, we have reported previously that dimerization alone is insufficient to activate full-length GHR. By comparing the crystal structure of the liganded and unliganded human GHR extracellular domain, we show here that there is no substantial change in its conformation on ligand binding. However, the receptor can be activated by rotation without ligand by inserting a defined number of alanine residues within the transmembrane domain. Fluorescence resonance energy transfer (FRET), bioluminescence resonance energy transfer (BRET) and coimmunoprecipitation studies suggest that receptor subunits undergo specific transmembrane interactions independent of hormone binding. We propose an activation mechanism involving a relative rotation of subunits within a dimeric receptor as a result of asymmetric placement of the receptor-binding sites on the ligand.
 
  Selected figure(s)  
 
Figure 1.
Figure 1. Crystal structure of unliganded hGHR ECD. (a) A ribbon diagram of the unliganded hGHR extracellular domain. Highlighted areas are the two hormone binding residues Trp104 and Trp169; in purple is the hormone binding region, in magenta is the flexible linker, and in light blue and green is the activation lock-and-key region ('dimerization domain'). (b) Stereo superimposition of C traces of hGHR from different crystal structures: molecule A in unliganded structure (blue), molecule B in unliganded structure (pink), 1:1 complex (green, PDB entry 1A22 chain B), 2:1 complex (purple, PDB entry 1HGW chain B), 2:1 complex (red, PDB entry 1HGW chain C).
Figure 7.
Figure 7. A schematic model of GHR activation. The hormone is depicted in blue ribbon style and JAK2 as ellipses. The first diagram shows the unliganded preformed hGHR dimer on the plasma membrane with the subunits sitting equivalently. In the center diagram, a hormone molecule binds via site 1 to the left-hand receptor molecule (receptor 1). This is the structure observed in the published 1:1 complex. The dimerization domains of each receptor (located in the C-terminal domains) are far from complementary because of charge repulsions and steric clashes. The right-hand diagram shows the structure as observed in the crystal structure of the published 2:1 complex. On binding to site 2 of the hormone, the second receptor molecule must move with respect to the first molecule so that the dimerization contacts are optimized, involving a rotation and a vertical movement. This then causes a rotation of the TMD and juxtamembrane regions, resulting in rotation and activation by transphosphorylation of the JAK2 molecules bound to box 1, and the initiation of the GHR signaling cascade. The red line indicates disulfide bond formation by Cys241, which occurs as a result of receptor activation28. See also http://www2.imb.uq.edu.au/groups/waters/hghr.html.
 
  The above figures are reprinted by permission from Macmillan Publishers Ltd: Nat Struct Mol Biol (2005, 12, 814-821) copyright 2005.  
  Figures were selected by the author.  

Literature references that cite this PDB file's key reference

  PubMed id Reference
20664532 A.J.Brooks, and M.J.Waters (2010).
The growth hormone receptor: mechanism of activation and clinical implications.
  Nat Rev Endocrinol, 6, 515-525.  
19996410 C.Pecquet, J.Staerk, R.Chaligné, V.Goss, K.A.Lee, X.Zhang, J.Rush, J.Van Hees, H.A.Poirel, J.M.Scheiff, W.Vainchenker, S.Giraudier, R.D.Polakiewicz, and S.N.Constantinescu (2010).
Induction of myeloproliferative disorder and myelofibrosis by thrombopoietin receptor W515 mutants is mediated by cytosolic tyrosine 112 of the receptor.
  Blood, 115, 1037-1048.  
19927328 D.Poger, and A.E.Mark (2010).
Turning the growth hormone receptor on: evidence that hormone binding induces subunit rotation.
  Proteins, 78, 1163-1174.  
20053995 I.Broutin, J.B.Jomain, E.Tallet, J.van Agthoven, B.Raynal, S.Hoos, B.B.Kragelund, P.A.Kelly, A.Ducruix, P.England, and V.Goffin (2010).
Crystal structure of an affinity-matured prolactin complexed to its dimerized receptor reveals the topology of hormone binding site 2.
  J Biol Chem, 285, 8422-8433.
PDB code: 3ew3
20149678 N.Binart, A.Bachelot, and J.Bouilly (2010).
Impact of prolactin receptor isoforms on reproduction.
  Trends Endocrinol Metab, 21, 362-368.  
20462497 S.I.Yoon, B.C.Jones, N.J.Logsdon, B.D.Harris, A.Deshpande, S.Radaeva, B.A.Halloran, B.Gao, and M.R.Walter (2010).
Structure and mechanism of receptor sharing by the IL-10R2 common chain.
  Structure, 18, 638-648.
PDB code: 3lqm
19535262 C.V.Clevenger, S.L.Gadd, and J.Zheng (2009).
New mechanisms for PRLr action in breast cancer.
  Trends Endocrinol Metab, 20, 223-229.  
19530249 D.Langosch, and I.T.Arkin (2009).
Interaction and conformational dynamics of membrane-spanning protein helices.
  Protein Sci, 18, 1343-1358.  
19658168 E.Stuttfeld, and K.Ballmer-Hofer (2009).
Structure and function of VEGF receptors.
  IUBMB Life, 61, 915-922.  
19483125 J.Ding, H.Komatsu, S.Iida, H.Yano, S.Kusumoto, A.Inagaki, F.Mori, M.Ri, A.Ito, A.Wakita, T.Ishida, M.Nitta, and R.Ueda (2009).
The Asn505 mutation of the c-MPL gene, which causes familial essential thrombocythemia, induces autonomous homodimerization of the c-Mpl protein due to strong amino acid polarity.
  Blood, 114, 3325-3328.  
19579232 J.J.Bustamante, L.Gonzalez, C.A.Carroll, S.T.Weintraub, R.M.Aguilar, J.Muñoz, A.O.Martinez, and L.S.Haro (2009).
O-Glycosylated 24 kDa human growth hormone has a mucin-like biantennary disialylated tetrasaccharide attached at Thr-60.
  Proteomics, 9, 3474-3488.  
19929035 M.R.Graham, P.Evans, N.E.Thomas, B.Davies, and J.S.Baker (2009).
Changes in Endothelial Dysfunction and Associated Cardiovascular Disease Morbidity Markers in GH-IGF Axis Pathology.
  Am J Cardiovasc Drugs, 9, 371-381.  
19382888 R.M.Eglen, and T.Reisine (2009).
The current status of drug discovery against the human kinome.
  Assay Drug Dev Technol, 7, 22-43.  
19884662 S.Melmed (2009).
Acromegaly pathogenesis and treatment.
  J Clin Invest, 119, 3189-3202.  
19139102 T.Hornakova, J.Staerk, Y.Royer, E.Flex, M.Tartaglia, S.N.Constantinescu, L.Knoops, and J.C.Renauld (2009).
Acute lymphoblastic leukemia-associated JAK1 mutants activate the Janus kinase/STAT pathway via interleukin-9 receptor alpha homodimers.
  J Biol Chem, 284, 6773-6781.  
19496166 W.Im, J.Lee, T.Kim, and H.Rui (2009).
Novel free energy calculations to explore mechanisms and energetics of membrane protein structure and function.
  J Comput Chem, 30, 1622-1633.  
17888716 A.J.Brooks, J.W.Wooh, K.A.Tunny, and M.J.Waters (2008).
Growth hormone receptor; mechanism of action.
  Int J Biochem Cell Biol, 40, 1984-1989.  
18570899 A.Whitty, and T.V.Riera (2008).
New ways to target old receptors.
  Curr Opin Chem Biol, 12, 427-433.  
18599299 B.C.Jones, N.J.Logsdon, and M.R.Walter (2008).
Structure of IL-22 bound to its high-affinity IL-22R1 chain.
  Structure, 16, 1333-1344.
PDB code: 3dgc
18246318 C.V.Clevenger, J.Zheng, E.M.Jablonski, T.L.Galbaugh, and F.Fang (2008).
From bench to bedside: future potential for the translation of prolactin inhibitors as breast cancer therapeutics.
  J Mammary Gland Biol Neoplasia, 13, 147-156.  
18081308 D.Tan, K.T.Huang, E.Ueda, and A.M.Walker (2008).
S2 deletion variants of human PRL receptors demonstrate that extracellular domain conformation can alter conformation of the intracellular signaling domain.
  Biochemistry, 47, 479-489.  
18219565 E.Tallet, V.Rouet, J.B.Jomain, P.A.Kelly, S.Bernichtein, and V.Goffin (2008).
Rational design of competitive prolactin/growth hormone receptor antagonists.
  J Mammary Gland Biol Neoplasia, 13, 105-117.  
18407771 F.Roelfsema, N.R.Biermasz, A.M.Pereira, and J.A.Romijn (2008).
The role of pegvisomant in the treatment of acromegaly.
  Expert Opin Biol Ther, 8, 691-704.  
18775332 G.Skiniotis, P.J.Lupardus, M.Martick, T.Walz, and K.C.Garcia (2008).
Structural organization of a full-length gp130/LIF-R cytokine receptor transmembrane complex.
  Mol Cell, 31, 737-748.
PDB code: 3e0g
18228541 J.Bacart, C.Corbel, R.Jockers, S.Bach, and C.Couturier (2008).
The BRET technology and its application to screening assays.
  Biotechnol J, 3, 311-324.  
18163211 J.D.Carmichael, and V.S.Bonert (2008).
Medical therapy: options and uses.
  Rev Endocr Metab Disord, 9, 71-81.  
18425004 J.Micallef, A.Gajadhar, J.Wiley, L.V.DeSouza, K.W.Michael Siu, and A.Guha (2008).
Proteomics: present and future implications in neuro-oncology.
  Neurosurgery, 62, 539.  
18467331 L.A.Svensson, K.Bondensgaard, L.Nørskov-Lauritsen, L.Christensen, P.Becker, M.D.Andersen, M.J.Maltesen, K.D.Rand, and J.Breinholt (2008).
Crystal structure of a prolactin receptor antagonist bound to the extracellular domain of the prolactin receptor.
  J Biol Chem, 283, 19085-19094.
PDB code: 3d48
18456658 M.Gakovic, J.Ragimbeau, V.Francois, S.N.Constantinescu, and S.Pellegrini (2008).
The Stat3-activating Tyk2 V678F mutant does not up-regulate signaling through the type I interferon receptor but confers ligand hypersensitivity to a homodimeric receptor.
  J Biol Chem, 283, 18522-18529.  
  18827854 M.R.Graham, P.Evans, B.Davies, and J.S.Baker (2008).
AAS, growth hormone, and insulin abuse: psychological and neuroendocrine effects.
  Ther Clin Risk Manag, 4, 587-597.  
  19337549 M.R.Graham, P.Evans, B.Davies, and J.S.Baker (2008).
Arterial pulse wave velocity, inflammatory markers, pathological GH and IGF states, cardiovascular and cerebrovascular disease.
  Vasc Health Risk Manag, 4, 1361-1371.  
18326494 M.Zaks-Zilberman, A.E.Harrington, T.Ishino, and I.M.Chaiken (2008).
Interleukin-5 receptor subunit oligomerization and rearrangement revealed by fluorescence resonance energy transfer imaging.
  J Biol Chem, 283, 13398-13406.  
18640841 P.De Meyts (2008).
The insulin receptor: a prototype for dimeric, allosteric membrane receptors?
  Trends Biochem Sci, 33, 376-384.  
18387308 P.Liu, S.Ahmed, and T.Wohland (2008).
The F-techniques: advances in receptor protein studies.
  Trends Endocrinol Metab, 19, 181-190.  
18345707 S.Benedini, I.Terruzzi, A.Lazzarin, and L.Luzi (2008).
Recombinant human growth hormone: rationale for use in the treatment of HIV-associated lipodystrophy.
  BioDrugs, 22, 101-112.  
18586085 S.J.Frank, and S.Y.Fuchs (2008).
Modulation of growth hormone receptor abundance and function: roles for the ubiquitin-proteasome system.
  Biochim Biophys Acta, 1782, 785-794.  
18381258 S.L.Varvio, T.Iso-Touru, J.Kantanen, S.Viitala, I.Tapio, A.Mäki-Tanila, M.Zerabruk, and J.Vilkki (2008).
Molecular anatomy of the cytoplasmic domain of bovine growth hormone receptor, a quantitative trait locus.
  Proc Biol Sci, 275, 1525-1534.  
18157698 S.Loeper, and S.Ezzat (2008).
Acromegaly: re-thinking the cancer risk.
  Rev Endocr Metab Disord, 9, 41-58.  
18488018 S.W.Rowlinson, H.Yoshizato, J.L.Barclay, A.J.Brooks, S.N.Behncken, L.M.Kerr, K.Millard, K.Palethorpe, K.Nielsen, J.Clyde-Smith, J.F.Hancock, and M.J.Waters (2008).
An agonist-induced conformational change in the growth hormone receptor determines the choice of signalling pathway.
  Nat Cell Biol, 10, 740-747.  
17671978 T.A.Wassenaar, W.J.Quax, and A.E.Mark (2008).
The conformation of the extracellular binding domain of Death Receptor 5 in the presence and absence of the activating ligand TRAIL: a molecular dynamics study.
  Proteins, 70, 333-343.  
18682296 W.Vainchenker, A.Dusa, and S.N.Constantinescu (2008).
JAKs in pathology: role of Janus kinases in hematopoietic malignancies and immunodeficiencies.
  Semin Cell Dev Biol, 19, 385-393.  
18829468 Y.Malka, T.Hornakova, Y.Royer, L.Knoops, J.C.Renauld, S.N.Constantinescu, and Y.I.Henis (2008).
Ligand-independent Homomeric and Heteromeric Complexes between Interleukin-2 or -9 Receptor Subunits and the {gamma} Chain.
  J Biol Chem, 283, 33569-33577.  
18252254 Z.Li, J.J.Strunk, P.Lamken, J.Piehler, and T.Walz (2008).
The EM structure of a type I interferon-receptor complex reveals a novel mechanism for cytokine signaling.
  J Mol Biol, 377, 715-724.  
17508727 B.M.Dattilo, G.Fritz, E.Leclerc, C.W.Kooi, C.W.Heizmann, and W.J.Chazin (2007).
The extracellular region of the receptor for advanced glycation end products is composed of two independent structural units.
  Biochemistry, 46, 6957-6970.  
17239579 D.Reichmann, O.Rahat, M.Cohen, H.Neuvirth, and G.Schreiber (2007).
The molecular architecture of protein-protein binding sites.
  Curr Opin Struct Biol, 17, 67-76.  
17391978 R.G.Rosenfeld, A.Belgorosky, C.Camacho-Hubner, M.O.Savage, J.M.Wit, and V.Hwa (2007).
Defects in growth hormone receptor signaling.
  Trends Endocrinol Metab, 18, 134-141.  
17917757 S.Fukamachi, and A.Meyer (2007).
Evolution of receptors for growth hormone and somatolactin in fish and land vertebrates: lessons from the lungfish and sturgeon orthologues.
  J Mol Evol, 65, 359-372.  
17723880 S.R.Buzzini (2007).
Abuse of growth hormone among young athletes.
  Pediatr Clin North Am, 54, 823.  
17722273 F.Roelfsema, N.R.Biermasz, A.M.Pereira, and J.Romijn (2006).
Nanomedicines in the treatment of acromegaly: focus on pegvisomant.
  Int J Nanomedicine, 1, 385-398.  
16914724 J.H.Kurzer, P.Saharinen, O.Silvennoinen, and C.Carter-Su (2006).
Binding of SH2-B family members within a potential negative regulatory region maintains JAK2 in an active state.
  Mol Cell Biol, 26, 6381-6394.  
17406254 K.D.Pfleger, R.M.Seeber, and K.A.Eidne (2006).
Bioluminescence resonance energy transfer (BRET) for the real-time detection of protein-protein interactions.
  Nat Protoc, 1, 337-345.  
16932322 M.O.Savage, K.M.Attie, A.David, L.A.Metherell, A.J.Clark, and C.Camacho-Hübner (2006).
Endocrine assessment, molecular characterization and treatment of growth hormone insensitivity disorders.
  Nat Clin Pract Endocrinol Metab, 2, 395-407.  
16774916 N.A.Noordeen, F.Carafoli, E.Hohenester, M.A.Horton, and B.Leitinger (2006).
A transmembrane leucine zipper is required for activation of the dimeric receptor tyrosine kinase DDR1.
  J Biol Chem, 281, 22744-22751.  
17009125 O.C.Wallis, and M.Wallis (2006).
Evolution of growth hormone in primates: the GH gene clusters of the New World monkeys marmoset (Callithrix jacchus) and white-fronted capuchin (Cebus albifrons).
  J Mol Evol, 63, 591-601.  
17024156 V.Goffin, P.Touraine, M.D.Culler, and P.A.Kelly (2006).
Drug Insight: prolactin-receptor antagonists, a novel approach to treatment of unresolved systemic and local hyperprolactinemia?
  Nat Clin Pract Endocrinol Metab, 2, 571-581.  
The most recent references are shown first. Citation data come partly from CiteXplore and partly from an automated harvesting procedure. Note that this is likely to be only a partial list as not all journals are covered by either method. However, we are continually building up the citation data so more and more references will be included with time. Where a reference describes a PDB structure, the PDB code is shown on the right.

 

spacer

spacer